VOR33 + VCAR33 Treatment System

The VOR33 + VCAR33 Treatment System has the potential to transform clinical outcomes for patients suffering with AML

The VOR33 + VCAR33 Treatment System is a novel and comprehensive approach that has the potential to transform clinical outcomes and establish a new standard of care for patients suffering with AML.

We believe VOR33 could unlock the potential of anti-CD33 therapies that are much more potent than Mylotarg™ such as VCAR33ALLO , which could be a highly potent anticancer therapy that, when combined with VOR33, is not associated with severe myeloablative toxicities.

An attractive feature of this Treatment System is that it uses the same allogeneic source of cells for both the eHSC and CAR-T. In this scenario, the apheresis product from the healthy donor can be processed to serve as starting materials for both products. One advantage of this approach is that donor derived T cells should not recognize CAR-T cells as foreign, potentially prolonging persistence. In addition, sourcing T cells from healthy donors may provide a healthier, more abundant cell source, allowing for optimizations and efficiencies in the manufacturing process that are not possible with autologous sources.

VOR33 + VCAR33 Treatment System—Clinical Development

We intend to submit an IND application with the FDA and conduct a clinical trial of the VOR33 + VCAR33 Treatment System after we obtain the initial results from our VOR33 Phase 1/2a clinical trial and our planned VCAR33ALLO Phase 1/2 monotherapy clinical trial. We believe demonstration of disease clearance activity by VCAR33ALLO would provide a fundamental rationale for further development in a non-relapse/refractory population which is still high risk, including patients with poor prognostic molecular markers and/or MRD positivity.

We would evaluate VCAR33ALLO in a post-VOR33 transplant setting to reduce the risk of recurrence or treat evidence of early relapse. Through use of VOR33, we believe VCAR33ALLO could be used in a post-transplant maintenance setting since CD33 negative hematopoiesis established by the VOR33 graft would be protected from eradication. The objective of this trial would be to assess the safety and initial clinical efficacy of the VOR33 + VCAR33 Treatment System.

Next In Our Pipeline

VOR33-CLL1 + VCAR33-CLL1 Treatment System